Scholarlink

<p>Sarcomas are rare, highly heterogeneous malignancies, with soft tissue sarcomas (STS) comprising nearly 80 histological subtypes. Localized STS is generally treated with surgery and radiotherapy, whereas metastatic disease relies largely on chemotherapy, which offers limited benefit. Although inflammation influences tumor development, treatment response, and prognosis, immune checkpoint inhibitors have shown minimal efficacy in sarcoma. The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway is linked to mutational burden, genomic instability, immune cell infiltration, and therapeutic response across multiple cancer types. However, its role in sarcoma remains unclear. In a newly established cohort of STS patients, we found that STING expression in primary tumors correlates with immune cell infiltration. Using a lipid nanoparticle (LNP)–mediated delivery of CRISPR activation mRNA components, we restored STING expression in STS cells, thereby reactivating cGAS–STING signaling. This promoted T‑cell recognition and tumor cell killing in both 2D and 3D patient-derived models and enhanced responses to anti-PD-1 treatment. Together, our results show that controlled epigenetic activation of STING in STS enhances immune infiltration and tumor cell killing. Targeting STING through CRISPR activation may therefore represent a promising therapeutic strategy for STS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月21日

查看全文
  • Stine Høvring Godsk,
  • Mireia Crus De los Santos,
  • Tobias Wang Bjerg,
  • Thomas Gravgaard Andersen,
  • Felix Haglund de Flon,
  • Maria Elisabeth Harder,
  • Anders Etzerodt,
  • Ninna Aggerholm-Pedersen,
  • Andreas Lundqvist,
  • Martin Roelsgaard Jakobsen

摘要

Sarcomas are rare, highly heterogeneous malignancies, with soft tissue sarcomas (STS) comprising nearly 80 histological subtypes. Localized STS is generally treated with surgery and radiotherapy, whereas metastatic disease relies largely on chemotherapy, which offers limited benefit. Although inflammation influences tumor development, treatment response, and prognosis, immune checkpoint inhibitors have shown minimal efficacy in sarcoma. The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) pathway is linked to mutational burden, genomic instability, immune cell infiltration, and therapeutic response across multiple cancer types. However, its role in sarcoma remains unclear. In a newly established cohort of STS patients, we found that STING expression in primary tumors correlates with immune cell infiltration. Using a lipid nanoparticle (LNP)–mediated delivery of CRISPR activation mRNA components, we restored STING expression in STS cells, thereby reactivating cGAS–STING signaling. This promoted T‑cell recognition and tumor cell killing in both 2D and 3D patient-derived models and enhanced responses to anti-PD-1 treatment. Together, our results show that controlled epigenetic activation of STING in STS enhances immune infiltration and tumor cell killing. Targeting STING through CRISPR activation may therefore represent a promising therapeutic strategy for STS.